Resigratinib

DB21664ExperimentalSmall molecule

Resigratinib is a small molecule drug. The usage of the INN stem '-gratinib' in the name indicates that Resigratinib is a fibroblast growth factor receptor (FGFR) inhibitor. Resigratinib has a... Resigratinib has a monoisotopic molecular weight of 523.21 Da.

Mechanism: Pharmacologically active on Fibroblast growth factor receptor
Curator reviewed
Formula / weight: C₂₆H₂₇F₂N₇O₃ · 523.545 g/mol (avg)

Resolves to

Compound

UNIIW728TB393WCAS2750709-91-0ChEMBLCHEMBL5314537ChEBI759238PubChem162381323

Structure

InChIKeyYXVDEILMUVTDMK-JKSUJKDBSA-NSMILESCNC1=C(C(N)=O)C(=NN1[C@H]1C[C@H](COC)N(C1)C(=O)C=C)C#CC1=C(F)C=C2N(C=NC2=C1F)C1CC1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Resigratinib, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account